BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 16118801)

  • 1. Impact of brachytherapy on regional, racial, marital status, and age-related patterns of definitive treatment for clinically localized prostate carcinoma.
    Copeland LA; Elshaikh MA; Jackson J; Penner LA; Underwood W
    Cancer; 2005 Oct; 104(7):1372-80. PubMed ID: 16118801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age.
    Terakedis BE; Rossi PJ; Liauw SL; Johnstone PA; Jani AB
    Am J Clin Oncol; 2010 Dec; 33(6):619-23. PubMed ID: 20051808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment decision-making strategies and influences in patients with localized prostate carcinoma.
    Gwede CK; Pow-Sang J; Seigne J; Heysek R; Helal M; Shade K; Cantor A; Jacobsen PB
    Cancer; 2005 Oct; 104(7):1381-90. PubMed ID: 16080181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical prostatectomy for clinical T4 prostate cancer.
    Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
    Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
    Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
    J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis.
    Shen X; Keith SW; Mishra MV; Dicker AP; Showalter TN
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1154-9. PubMed ID: 22270175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.
    Kälkner KM; Wahlgren T; Ryberg M; Cohn-Cedermark G; Castellanos E; Zimmerman R; Nilsson J; Lundell M; Fowler J; Levitt S; Hellström M; Nilsson S
    Acta Oncol; 2007; 46(7):909-17. PubMed ID: 17917823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
    Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
    Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
    Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR;
    J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma.
    D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
    Cancer; 2003 Jan; 97(1):56-62. PubMed ID: 12491505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.
    Guzzo TJ; Levin BM; Lee R; Guo M; Chen Z; Whittington R; Tomaszewski J; Malkowicz SB
    Urology; 2008 Apr; 71(4):723-7. PubMed ID: 18387401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis.
    Chang DT; Chapman C; Shen J; Su Z; Koong AC
    Am J Clin Oncol; 2009 Aug; 32(4):405-10. PubMed ID: 19415029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
    Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
    Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
    Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.